References
- Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069–77.
- Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am 2018;32:1–10.
- Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, Van Rhee F, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol 2016;3:e163–75.
- Suwannaroj S, Elkins SL, McMurray RW. Systemic lupus erythematosus and Castleman’s disease. J Rheumatol 1999;26:1400–3.
- Higashi K, Matsuki Y, Hidaka T, Aida S, Suzuki K, Nakamura H. Primary Sjögren’s syndrome associated with hyaline-vascular type of Castleman’s disease and autoimmune idiopathic thrombocytopenia. Scand J Rheumatol 1997;26:482–4.
- Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am 2018;32:11–21.
- Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670–83.
- Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017;129:1646–57.
- Fajgenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. The collaborative network approach: a new framework to accelerate Castleman’s disease and other rare disease research. Lancet Haematol 2016;3:e150–52.
- Van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018;132:2115–24.